In vitro Microbiology
Pharmacology Discovery Services provides a robust portfolio of both in vitro potency and in vivo efficacy antimicrobial services to support the discovery and development of novel antimicrobials in our BSL-2 facility.
With a comprehensive collection of more than 750 clinically relevant Gram-positive and Gram-negative bacteria including multi-drug resistant (MDR) organisms, anaerobic bacteria, yeast, and filamentous fungi, we provide in vitro antimicrobial services to help your drug development program succeed. Most strains are phenotyped and the acquired antibiotic resistance genes are genotyped. To accelerate your MIC testing, fungal, bacterial and N. gonorrhoeae pre-designed panels are also available. The minimum bactericidal concentration (MBC) may be determined following the M26-A guidelines of the Clinical and Laboratory Standards Institute.
The Minimum Inhibitory Concentration (MIC) testing from Pharmacology Discovery Services has over 750 strains of clinically relevant pathogens, including:
- Bacteria – aerobes and anaerobes
- Multidrug Resistant Strains (MDR) – E. coli, K. pneumoniae, N. gonorrhoeae, A. baumannii, P. aeruginosa, Enterococcus, Staphylococcus and Streptococcus
- Fungi – yeasts, molds and dermatophytes
- Characterization – most strains are phenotyped
To accelerate MIC testing off-the-shelf panels are available:
- Bacterial, Fungal, N. gonorrhoeae and ESKAPE pathogens
- Custom MIC panels - can be created with any of our available strains
- Minimum bactericidal concentration (MBC) - may be determined following the M26-A guidelines of the Clinical and Laboratory Standards Institute
Once MIC testing is complete we have a selection of other In vitro assays to further characterize antimicrobial compounds, including:
- Time Kill Assay – to determine if a compound has microbicidal properties
- Checkerboard Assay – to assess antimicrobial potency of two compounds alone and in combination
- Resistance Emergence – a group of custom assays to measure the frequency of resistance emergence
- Membrane Lysis Assay - to detect the disruption of S. aureus cell membrane
- Red Blood Lysis – to test if a compound can lyse human RBCs
- Cytotoxicity Assays - to measure cytotoxicity, 40 human and rodent cell lines are available
Ordering MIC Assays
There are two options available to place an order for MIC assays. You may complete an order form and contact our client services department or you may place an order using the eCommerce system from our partner lab Eurofins Pharma Discovery Services.
- OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections. Kers JA et al., PLoS One. 2018 Jun 12;13(6).
- In Vitro and In Vivo Efficacy of a Novel and Long-Acting Fungicidal Azole, PC1244, on Aspergillus fumigatus Infection. Colley T et al., Antimicrob Agents Chemother. 2018 Apr 26;62(5).
- Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection. Kers JA et al., Front Microbiol. 2018 Mar 16;9:415.
- In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice. Kimura G et al., Antimicrob Agents Chemother. 2017 Aug 24;61(9).
- Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. Yates CM et al., Bioorg Med Chem Lett. 2017 Aug 1;27(15):3243-3248.
- In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection. Colley T et al., Antimicrob Agents Chemother. 2017 Apr 24;61(5).